Niagen Bioscience posts investor deck outlining NAD+ healthy-aging strategy

Niagen Bioscience, Inc.

Niagen Bioscience, Inc.

NAGE

0.00
  • Niagen Bioscience investor presentation outlined strategy to expand NAD+ franchise across consumer supplements, IV therapies, injections, skincare.
  • Q1 2026 LTM metrics showed USD 130.4 million revenue, USD 18.6 million net income, USD 66.5 million cash, no debt.
  • Niagen IV and injectables push targeted NAD+ IV market sized at about USD 300 million, positioned as faster to administer with fewer side effects versus NAD+ IV.
  • Early traction cited for Niagen IV, including more than 1,500 clinics onboarded since August 2024, USD 6.4 million ingredient sales since launch.
  • Product development highlighted Niagen NanoCloud topical format, positioned as waterless delivery to reduce degradation risk seen in water-based NAD+ skincare.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.